US 12,403,141 B2
Deuterated MK2 pathway inhibitors and methods of using the same
David Randolph Anderson, Salem, CT (US); and Gary Anthony Decrescenzo, Parkville, MO (US)
Assigned to Aclaris Therapeutics, Inc., Wayne, PA (US)
Appl. No. 17/630,414
Filed by ACLARIS THERAPEUTICS, INC., Wayne, PA (US)
PCT Filed Jul. 31, 2020, PCT No. PCT/US2020/044558
§ 371(c)(1), (2) Date Jan. 26, 2022,
PCT Pub. No. WO2021/022186, PCT Pub. Date Feb. 4, 2021.
Claims priority of provisional application 62/881,026, filed on Jul. 31, 2019.
Prior Publication US 2022/0288070 A1, Sep. 15, 2022
Int. Cl. A61K 31/506 (2006.01); A61P 35/00 (2006.01); A61P 37/02 (2006.01); C07D 401/14 (2006.01)
CPC A61K 31/506 (2013.01) [A61P 35/00 (2018.01); A61P 37/02 (2018.01); C07D 401/14 (2013.01)] 7 Claims
 
1. A compound having the structure:

OG Complex Work Unit Chemistry
3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy-d2)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2H-[1,4′-bipyridin]-2-one, or a pharmaceutically acceptable salt thereof, wherein 3-Chloro-4-((3,5-difluoropyridin-2-yl) methoxy-d2)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2H-[1,4′-bipyridin]-2-one, or a pharmaceutically acceptable salt thereof, is a single atropisomer and wherein the single atropisomer is (P)-3-Chloro-4-((3,5-difluoropyridin-2-yl) methoxy-d2)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2H-[1,4′-bipyridin]-2-one, or a pharmaceutically acceptable salt thereof.